However, the extension of the scope from single-gene testing to multiplex genetic panel testing (MGPT), including TP53, has improved the detection rate of germline TP53 variants in patients with breast cancer even if they do not fulfill the clinical testing criteria in China [3]. Here, TP53 is linked to breast cancer.